Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study

Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study

We hypothesized that sorafenib plus transarterial chemoembolization (TACE) would confer survival benefits over sorafenib alone for advanced hepatocellular carcinoma (aHCC). We investigated this while using the population-based All-Cancer Dataset to assemble a cohort (<i>n</i> = 3674; med...

Full description

Bibliographic Details
Main Authors: Victor C. Kok, Yu-Ching Chen, Yang-Yuan Chen, Yu-Chieh Su, Ming-Chang Ku, Jung-Tsung Kuo, Go J. Yoshida
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cancers
Subjects:
sorafenib
hepatocellular carcinoma
transarterial chemoembolization
add-on therapy
propensity analysis
Online Access:https://www.mdpi.com/2072-6694/11/7/985

Similar Items

Similar Items